Outcomes following three-line vision loss during treatment of neovascular age-related macular degeneration: subgroup analyses from MARINA and ANCHOR
Identifieur interne : 006259 ( Main/Exploration ); précédent : 006258; suivant : 006260Outcomes following three-line vision loss during treatment of neovascular age-related macular degeneration: subgroup analyses from MARINA and ANCHOR
Auteurs : Sebastian Wolf [Suisse] ; Frank G. Holz [Allemagne] ; Jean-François Korobelnik [France] ; Paolo Lanzetta [Italie] ; Paul Mitchell [Australie] ; Christian Prünte [Autriche] ; Ursula Schmidt-Erfurth [Autriche] ; Andreas Weichselberger [Suisse] ; Yehia Hashad [Suisse]Source :
- British Journal of Ophthalmology [ 0007-1161 ] ; 2011-12.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Acuity, Acute bcva loss, Age related macular degeneration, Analysis, Anchor patients, Anchor study, Anchor trials, Baseline, Baseline characteristics, Bcva, Bcva change, Bcva loss, Bcva outcomes, Blindness, Choroidal neovascularisation, Classic occult, Control patients, Degeneration, Evolution, Intraocular pressure, Macular, Macular degeneration, Marina trials, Neovascular, Neovascular macular degeneration, Neovascularization, Novartis, Novartis pharma, Ophthalmol, Ophthalmology, Pharma, Photodynamic treatment, Prognosis, Ranibizumab, Ranibizumab treatment, Retinal pigment epithelium, Severe bcva loss, Sham, Sham control group, Sham treatment, Study baseline, Total area, Treatment, Visual acuity.
- Teeft :
- Acuity, Acute bcva loss, Anchor patients, Anchor study, Anchor trials, Baseline, Baseline characteristics, Bcva, Bcva change, Bcva loss, Bcva outcomes, Choroidal neovascularisation, Classic occult, Control patients, Degeneration, Intraocular pressure, Macular, Macular degeneration, Marina trials, Neovascular, Neovascular macular degeneration, Novartis, Novartis pharma, Ophthalmol, Ophthalmology, Pharma, Photodynamic treatment, Ranibizumab, Ranibizumab treatment, Retinal pigment epithelium, Severe bcva loss, Sham, Sham control group, Sham treatment, Study baseline, Total area, Visual acuity.
Abstract
Aim This study aims to assess the impact of continued ranibizumab treatment for neovascular age-related macular degeneration on patients from the MARINA and ANCHOR randomised clinical studies who lost ≥3 lines of best-corrected visual acuity (BCVA) at any time during the first year of treatment. Methods Baseline characteristics, mean BCVA over time and ocular adverse events (AEs) were evaluated both for patients whose BCVA loss occurred at any post-baseline visit and for patients whose BCVA loss was acute. The visit when the ≥3-line BCVA loss was detected was defined as the new baseline. Results Continued monthly ranibizumab treatment led to an improvement in mean BCVA from the new baseline. On average, patients with acute BCVA loss gained 11.9 letters at 3 months after the new baseline, compared with 0.3 letters gained with sham. No strong signals were detected in patient demographics and baseline characteristics for prognostic markers of BCVA loss. Furthermore, there was no pattern in the AE profile of patients with acute BCVA loss to suggest that BCVA recovery could be attributed to spontaneously resolving AEs. Conclusion Continued ranibizumab treatment appears to be beneficial for patients with neovascular age-related macular degeneration who experience a ≥3-line BCVA loss during the first year of treatment.
Url:
DOI: 10.1136/bjophthalmol-2011-300471
Affiliations:
- Allemagne, Australie, Autriche, France, Italie, Suisse
- Aquitaine, Canton de Berne, District de Cologne, Nouvelle-Aquitaine, Nouvelle-Galles du Sud, Rhénanie-du-Nord-Westphalie, Vienne (Autriche)
- Berne, Bonn, Bordeaux, Sydney, Vienne (Autriche)
- Université de Berne, Université de Sydney
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000287
- to stream Istex, to step Curation: 000287
- to stream Istex, to step Checkpoint: 000678
- to stream Main, to step Merge: 006635
- to stream PascalFrancis, to step Corpus: 001758
- to stream PascalFrancis, to step Curation: 004751
- to stream PascalFrancis, to step Checkpoint: 001820
- to stream Main, to step Merge: 006C71
- to stream Main, to step Curation: 006259
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Outcomes following three-line vision loss during treatment of neovascular age-related macular degeneration: subgroup analyses from MARINA and ANCHOR</title><author><name sortKey="Wolf, Sebastian" sort="Wolf, Sebastian" uniqKey="Wolf S" first="Sebastian" last="Wolf">Sebastian Wolf</name></author><author><name sortKey="Holz, Frank G" sort="Holz, Frank G" uniqKey="Holz F" first="Frank G" last="Holz">Frank G. Holz</name></author><author><name sortKey="Korobelnik, Jean Francois" sort="Korobelnik, Jean Francois" uniqKey="Korobelnik J" first="Jean-François" last="Korobelnik">Jean-François Korobelnik</name></author><author><name sortKey="Lanzetta, Paolo" sort="Lanzetta, Paolo" uniqKey="Lanzetta P" first="Paolo" last="Lanzetta">Paolo Lanzetta</name></author><author><name sortKey="Mitchell, Paul" sort="Mitchell, Paul" uniqKey="Mitchell P" first="Paul" last="Mitchell">Paul Mitchell</name></author><author><name sortKey="Prunte, Christian" sort="Prunte, Christian" uniqKey="Prunte C" first="Christian" last="Prünte">Christian Prünte</name></author><author><name sortKey="Schmidt Erfurth, Ursula" sort="Schmidt Erfurth, Ursula" uniqKey="Schmidt Erfurth U" first="Ursula" last="Schmidt-Erfurth">Ursula Schmidt-Erfurth</name></author><author><name sortKey="Weichselberger, Andreas" sort="Weichselberger, Andreas" uniqKey="Weichselberger A" first="Andreas" last="Weichselberger">Andreas Weichselberger</name></author><author><name sortKey="Hashad, Yehia" sort="Hashad, Yehia" uniqKey="Hashad Y" first="Yehia" last="Hashad">Yehia Hashad</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0EA0A7DB371B32F399090BF2815A30A4808B837E</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1136/bjophthalmol-2011-300471</idno><idno type="url">https://api.istex.fr/document/0EA0A7DB371B32F399090BF2815A30A4808B837E/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000287</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000287</idno><idno type="wicri:Area/Istex/Curation">000287</idno><idno type="wicri:Area/Istex/Checkpoint">000678</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000678</idno><idno type="wicri:doubleKey">0007-1161:2011:Wolf S:outcomes:following:three</idno><idno type="wicri:Area/Main/Merge">006635</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:12-0008259</idno><idno type="wicri:Area/PascalFrancis/Corpus">001758</idno><idno type="wicri:Area/PascalFrancis/Curation">004751</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001820</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001820</idno><idno type="wicri:doubleKey">0007-1161:2011:Wolf S:outcomes:following:three</idno><idno type="wicri:Area/Main/Merge">006C71</idno><idno type="wicri:Area/Main/Curation">006259</idno><idno type="wicri:Area/Main/Exploration">006259</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Outcomes following three-line vision loss during treatment of neovascular age-related macular degeneration: subgroup analyses from MARINA and ANCHOR</title><author><name sortKey="Wolf, Sebastian" sort="Wolf, Sebastian" uniqKey="Wolf S" first="Sebastian" last="Wolf">Sebastian Wolf</name><affiliation wicri:level="4"><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Ophthalmology, Inselspital, University of Bern, Bern</wicri:regionArea><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region><settlement type="city">Berne</settlement></placeName><orgName type="university">Université de Berne</orgName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Suisse</country></affiliation></author><author><name sortKey="Holz, Frank G" sort="Holz, Frank G" uniqKey="Holz F" first="Frank G" last="Holz">Frank G. Holz</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Ophthalmology, University of Bonn, Bonn</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Cologne</region><settlement type="city">Bonn</settlement></placeName></affiliation></author><author><name sortKey="Korobelnik, Jean Francois" sort="Korobelnik, Jean Francois" uniqKey="Korobelnik J" first="Jean-François" last="Korobelnik">Jean-François Korobelnik</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Department of Ophthalmology, CHU Bordeaux, Université Bordeaux 2, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Lanzetta, Paolo" sort="Lanzetta, Paolo" uniqKey="Lanzetta P" first="Paolo" last="Lanzetta">Paolo Lanzetta</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Ophthalmology, University of Udine, Udine</wicri:regionArea><wicri:noRegion>Udine</wicri:noRegion></affiliation></author><author><name sortKey="Mitchell, Paul" sort="Mitchell, Paul" uniqKey="Mitchell P" first="Paul" last="Mitchell">Paul Mitchell</name><affiliation wicri:level="4"><country xml:lang="fr">Australie</country><wicri:regionArea>Discipline of Ophthalmology, University of Sydney, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region><settlement type="city">Sydney</settlement></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Prunte, Christian" sort="Prunte, Christian" uniqKey="Prunte C" first="Christian" last="Prünte">Christian Prünte</name><affiliation wicri:level="3"><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Schmidt Erfurth, Ursula" sort="Schmidt Erfurth, Ursula" uniqKey="Schmidt Erfurth U" first="Ursula" last="Schmidt-Erfurth">Ursula Schmidt-Erfurth</name><affiliation wicri:level="3"><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Weichselberger, Andreas" sort="Weichselberger, Andreas" uniqKey="Weichselberger A" first="Andreas" last="Weichselberger">Andreas Weichselberger</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Hashad, Yehia" sort="Hashad, Yehia" uniqKey="Hashad Y" first="Yehia" last="Hashad">Yehia Hashad</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation><affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">British Journal of Ophthalmology</title><title level="j" type="abbrev">Br J Ophthalmol</title><idno type="ISSN">0007-1161</idno><idno type="eISSN">1468-2079</idno><imprint><publisher>BMJ Publishing Group Ltd.</publisher><pubPlace>BMA House, Tavistock Square, London, WC1H 9JR</pubPlace><date type="published" when="2011-12">2011-12</date><biblScope unit="volume">95</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1713">1713</biblScope></imprint><idno type="ISSN">0007-1161</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0007-1161</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acuity</term><term>Acute bcva loss</term><term>Age related macular degeneration</term><term>Analysis</term><term>Anchor patients</term><term>Anchor study</term><term>Anchor trials</term><term>Baseline</term><term>Baseline characteristics</term><term>Bcva</term><term>Bcva change</term><term>Bcva loss</term><term>Bcva outcomes</term><term>Blindness</term><term>Choroidal neovascularisation</term><term>Classic occult</term><term>Control patients</term><term>Degeneration</term><term>Evolution</term><term>Intraocular pressure</term><term>Macular</term><term>Macular degeneration</term><term>Marina trials</term><term>Neovascular</term><term>Neovascular macular degeneration</term><term>Neovascularization</term><term>Novartis</term><term>Novartis pharma</term><term>Ophthalmol</term><term>Ophthalmology</term><term>Pharma</term><term>Photodynamic treatment</term><term>Prognosis</term><term>Ranibizumab</term><term>Ranibizumab treatment</term><term>Retinal pigment epithelium</term><term>Severe bcva loss</term><term>Sham</term><term>Sham control group</term><term>Sham treatment</term><term>Study baseline</term><term>Total area</term><term>Treatment</term><term>Visual acuity</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Analyse</term><term>Cécité</term><term>Dégénérescence maculaire liée à l'âge</term><term>Evolution</term><term>Néovascularisation</term><term>Ophtalmologie</term><term>Pronostic</term><term>Traitement</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Acuity</term><term>Acute bcva loss</term><term>Anchor patients</term><term>Anchor study</term><term>Anchor trials</term><term>Baseline</term><term>Baseline characteristics</term><term>Bcva</term><term>Bcva change</term><term>Bcva loss</term><term>Bcva outcomes</term><term>Choroidal neovascularisation</term><term>Classic occult</term><term>Control patients</term><term>Degeneration</term><term>Intraocular pressure</term><term>Macular</term><term>Macular degeneration</term><term>Marina trials</term><term>Neovascular</term><term>Neovascular macular degeneration</term><term>Novartis</term><term>Novartis pharma</term><term>Ophthalmol</term><term>Ophthalmology</term><term>Pharma</term><term>Photodynamic treatment</term><term>Ranibizumab</term><term>Ranibizumab treatment</term><term>Retinal pigment epithelium</term><term>Severe bcva loss</term><term>Sham</term><term>Sham control group</term><term>Sham treatment</term><term>Study baseline</term><term>Total area</term><term>Visual acuity</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Aim This study aims to assess the impact of continued ranibizumab treatment for neovascular age-related macular degeneration on patients from the MARINA and ANCHOR randomised clinical studies who lost ≥3 lines of best-corrected visual acuity (BCVA) at any time during the first year of treatment. Methods Baseline characteristics, mean BCVA over time and ocular adverse events (AEs) were evaluated both for patients whose BCVA loss occurred at any post-baseline visit and for patients whose BCVA loss was acute. The visit when the ≥3-line BCVA loss was detected was defined as the new baseline. Results Continued monthly ranibizumab treatment led to an improvement in mean BCVA from the new baseline. On average, patients with acute BCVA loss gained 11.9 letters at 3 months after the new baseline, compared with 0.3 letters gained with sham. No strong signals were detected in patient demographics and baseline characteristics for prognostic markers of BCVA loss. Furthermore, there was no pattern in the AE profile of patients with acute BCVA loss to suggest that BCVA recovery could be attributed to spontaneously resolving AEs. Conclusion Continued ranibizumab treatment appears to be beneficial for patients with neovascular age-related macular degeneration who experience a ≥3-line BCVA loss during the first year of treatment.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Autriche</li><li>France</li><li>Italie</li><li>Suisse</li></country><region><li>Aquitaine</li><li>Canton de Berne</li><li>District de Cologne</li><li>Nouvelle-Aquitaine</li><li>Nouvelle-Galles du Sud</li><li>Rhénanie-du-Nord-Westphalie</li><li>Vienne (Autriche)</li></region><settlement><li>Berne</li><li>Bonn</li><li>Bordeaux</li><li>Sydney</li><li>Vienne (Autriche)</li></settlement><orgName><li>Université de Berne</li><li>Université de Sydney</li></orgName></list><tree><country name="Suisse"><region name="Canton de Berne"><name sortKey="Wolf, Sebastian" sort="Wolf, Sebastian" uniqKey="Wolf S" first="Sebastian" last="Wolf">Sebastian Wolf</name></region><name sortKey="Hashad, Yehia" sort="Hashad, Yehia" uniqKey="Hashad Y" first="Yehia" last="Hashad">Yehia Hashad</name><name sortKey="Weichselberger, Andreas" sort="Weichselberger, Andreas" uniqKey="Weichselberger A" first="Andreas" last="Weichselberger">Andreas Weichselberger</name><name sortKey="Wolf, Sebastian" sort="Wolf, Sebastian" uniqKey="Wolf S" first="Sebastian" last="Wolf">Sebastian Wolf</name></country><country name="Allemagne"><region name="Rhénanie-du-Nord-Westphalie"><name sortKey="Holz, Frank G" sort="Holz, Frank G" uniqKey="Holz F" first="Frank G" last="Holz">Frank G. Holz</name></region></country><country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Korobelnik, Jean Francois" sort="Korobelnik, Jean Francois" uniqKey="Korobelnik J" first="Jean-François" last="Korobelnik">Jean-François Korobelnik</name></region></country><country name="Italie"><noRegion><name sortKey="Lanzetta, Paolo" sort="Lanzetta, Paolo" uniqKey="Lanzetta P" first="Paolo" last="Lanzetta">Paolo Lanzetta</name></noRegion></country><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Mitchell, Paul" sort="Mitchell, Paul" uniqKey="Mitchell P" first="Paul" last="Mitchell">Paul Mitchell</name></region></country><country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Prunte, Christian" sort="Prunte, Christian" uniqKey="Prunte C" first="Christian" last="Prünte">Christian Prünte</name></region><name sortKey="Schmidt Erfurth, Ursula" sort="Schmidt Erfurth, Ursula" uniqKey="Schmidt Erfurth U" first="Ursula" last="Schmidt-Erfurth">Ursula Schmidt-Erfurth</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006259 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006259 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:0EA0A7DB371B32F399090BF2815A30A4808B837E
|texte= Outcomes following three-line vision loss during treatment of neovascular age-related macular degeneration: subgroup analyses from MARINA and ANCHOR
}}
| This area was generated with Dilib version V0.6.33. |  |